TY - JOUR
T1 - The protective role of the microenvironment in hairy cell leukemia treatment
T2 - Facts and perspectives
AU - Gargiulo, Ernesto
AU - Giordano, Mirta
AU - Niemann, Carsten U.
AU - Moussay, Etienne
AU - Paggetti, Jérôme
AU - Morande, Pablo Elías
N1 - Funding Information:
This work was supported by grants from the Luxembourg National Research Fund (FNR) and Fondation Cancer to EG, EM and JP (PRIDE15/10675146/CANBIO, C20/BM/14582635, and C20/BM/14592342), from FNRS-Télévie and the European commission to PM (7.8506.19, H2020-MSCA-IF-2020: 101029602), from CONICET, Argentina to MG and from the Danish Cancer Society and the EU funded ERA PERMED program to CN.
Publisher Copyright:
Copyright © 2023 Gargiulo, Giordano, Niemann, Moussay, Paggetti and Morande.
PY - 2023/3/8
Y1 - 2023/3/8
N2 - Hairy cell leukemia (HCL) is an incurable, rare lymphoproliferative hematological malignancy of mature B cAlthough first line therapy with purine analogues leads to positive results, almost half of HCL patients relapse after 5-10 years, and standard treatment may not be an option due to intolerance or refractoriness. Proliferation and survival of HCL cells is regulated by surrounding accessory cells and soluble signals present in the tumor microenvironment, which actively contributes to disease progression. In vitro studies show that different therapeutic approaches tested in HCL impact the tumor microenvironment, and that this milieu offers a protection affecting treatment efficacy. Herein we explore the effects of the tumor microenvironment to different approved and experimental therapeutic options for HCL. Dissecting the complex interactions between leukemia cells and their milieu will be essential to develop new targeted therapies for HCL patients.
AB - Hairy cell leukemia (HCL) is an incurable, rare lymphoproliferative hematological malignancy of mature B cAlthough first line therapy with purine analogues leads to positive results, almost half of HCL patients relapse after 5-10 years, and standard treatment may not be an option due to intolerance or refractoriness. Proliferation and survival of HCL cells is regulated by surrounding accessory cells and soluble signals present in the tumor microenvironment, which actively contributes to disease progression. In vitro studies show that different therapeutic approaches tested in HCL impact the tumor microenvironment, and that this milieu offers a protection affecting treatment efficacy. Herein we explore the effects of the tumor microenvironment to different approved and experimental therapeutic options for HCL. Dissecting the complex interactions between leukemia cells and their milieu will be essential to develop new targeted therapies for HCL patients.
KW - HCL
KW - leukemia microenvironment
KW - microenvironment targeting
KW - novel therapies
KW - treatment resistance
UR - http://www.scopus.com/inward/record.url?scp=85150727118&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/36968995
U2 - 10.3389/fonc.2023.1122699
DO - 10.3389/fonc.2023.1122699
M3 - Review article
C2 - 36968995
AN - SCOPUS:85150727118
SN - 2234-943X
VL - 13
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1122699
ER -